The independent source for health policy research, polling, and news.
Showing 81 - 100 of 259
The state’s governor said the plan has the full support of the White House. But the Trump administration was noncommittal about whether allowing states to buy and import cheaper drugs from up north could be the answer to the nation’s drug-pricing problem.
Support for “Medicare-for-all” is becoming a front-runner topic among Democratic presidential candidates. But the phrase is being used to describe any number of policies.
The recent declaration by President Donald Trump that taming unexpected medical bills would be a top priority for his administration echoed through the halls of Congress.
Emboldened by midterm election results and interest in possible presidential runs, Democrats are advancing a slew of new and old legislative proposals. It’s not yet clear, though, which if any could go the distance.
A reporter with a serious peanut allergy explains what it is like to process news reports that tout new pharmaceutical products that might minimize the danger of accidental exposure.
Medicare and Medicaid are fine, but the food safety component of the Food and Drug Administration and bio-threat surveillance done by the Department of Homeland Security are among the public health functions feeling the pinch.
States that have legalized marijuana are trying to set standards for pot impairment that would help keep the roadways safe. But the science behind it is not clear-cut.
The complete findings of a recent study show the FDA-approved drug Vascepa reduced the likelihood of cardiovascular death, stroke and other heart conditions in some patients. But science didn’t find the same promise for over-the-counter fish oil supplements when tested in healthy people.
Hospitals are increasingly advertising medical services directly to patients to enhance their national brands. They think the image building improves their ability to negotiate with health plans and brings in wealthier patients.
Critics worry the marketing of Vascepa, a purified fish oil product, could prove a fish story.
The state-federal health insurance program is more popular than ever. Now, states that want to expand eligibility are devising new strategies to pay for it — creating, in many red states, a significant political challenge.
This gap in the 2010 health law means health insurance remains unaffordable for millions of Americans. For now, relief is hard to come by.
Candidates are charging toward midterm elections on a platform of single-payer and universal coverage rhetoric. Yet “Medicare-for-all” and single-payer mean different things to different people.
Drug pricing is a top issue in the run-up to the midterm elections.
Health insurers and pharmacy benefit managers are exploring how two legal provisions — which have been on the books for decades — could bring down the price tags of certain prescription medications.
Trump administration officials say the policy would promote “immigrant self-sufficiency and protect finite resources.” Critics say it could have serious public health consequences.
At least 11 states are going to try to tax opioids despite pushback from pharmaceutical companies.
Among candidates running for Congress in upcoming elections are a smattering of left-leaning physicians who present a stark contrast to the predominantly Republican physicians currently in office.
Federal officials are proposing a rule to prohibit home health aides paid directly by Medicaid from having their dues for the powerful Service Employees International Union automatically deducted from their paychecks. The effort would likely mean those workers are far less likely to pay dues and could diminish the union’s influence.
Young physicians are pushing the medical establishment to rethink its long-held opposition. The political fallout could be substantial.
Stay informed by signing up for the Morning Briefing and other emails:
© 2026 KFF